Trending topics
#
Bonk Eco continues to show strength amid $USELESS rally
#
Pump.fun to raise $1B token sale, traders speculating on airdrop
#
Boop.Fun leading the way with a new launchpad on Solana.
$LLY said its oral GLP-1 orforglipron beat oral semaglutide in a 52-week head-to-head diabetes trial (The Lancet). A1C fell 2.2% w/ orforglipron 36mg vs 1.4% with semaglutide 14mg, and weight loss was 19.7lbs (9.2%) vs 11lbs (5.3%). Discontinuations were higher with orforglipron.
Top
Ranking
Favorites
